The optimization of therapeutic antibodies is time-intensive and resource-demanding, largely
because of the low-throughput screening of full-length antibodies (approximately 1 × 10 3 …

The continual evolution of SARS-CoV-2 and the emergence of variants that show resistance
to vaccines and neutralizing antibodies threaten to prolong the COVID-19 pandemic. …

Towards the end of 2021, SARS-CoV-2 vaccine effectiveness was threatened by the
emergence of the omicron clade (B. 1.1. 529), with more than 30 mutations in the spike protein. …

(A) Differences from BA. 2 in BA. 2.75 (orange), and BA. 2.75. 2 (red, underlined), depicted
upon the SARS-CoV-2 BA. 2 receptor binding domain (pdb: 7UB0). Sensitivity of SARS-CoV-…

Background The SARS-CoV-2 omicron (B.1.1.529) variant, which was first identified in
November, 2021, spread rapidly in many countries, with a spike protein highly diverged from …

COVID-19 disease outcome is highly dependent on adaptive immunity from T and B
lymphocytes, which play a critical role in the control, clearance and long-term protection against …

The capacity of humoral B cell-mediated immunity to effectively respond to and protect
against pathogenic infections is largely driven by the presence of a diverse repertoire of …

Characterization of COVID-19 antibodies has largely focused on memory B cells; however,
it is the antibody-secreting plasma cells that are directly responsible for the production of …

The recently-emerged SARS-CoV-2 B.1.1.529 variant (Omicron) is spreading rapidly in many
countries, with a spike that is highly diverged from the pandemic founder, raising fears that …

Advances in reading, writing, and editing DNA are providing unprecedented insights into
the complexity of immunological systems. This combination of systems and synthetic biology …